Bioprinting Liability Gap Threatens Hospital Operations, RMIT Research Warns

When a hospital prints a human organ and something fails, existing legal frameworks offer almost no guidance. Dr. Modupe B. Adewale, a PhD researcher at RMIT University's College of Business and Law, spent three years building a framework she calls Moralist Bio-Utilitarianism precisely because neither utilitarian nor rights-based bioethics could handle the problem alone.

"Pure utilitarian approaches can be very permissive," Dr. Adewale told me. "They can justify strong forms of commodification or prioritize aggregate benefit in ways that underplay concerns about exploitation or unequal access."

The liability question is the immediate practical problem, and the existing framework gives courts very little to work with.

The Manufacturing Identity Crisis

Product liability law draws a firm line between manufacturers, who face strict liability, and clinicians, who are held to a negligence standard. That distinction held up reasonably well when hospitals simply used medical devices.

But when a hospital designs, fabricates, and implants a bioprinted organ in-house, Dr. Adewale argues the institution is no longer merely using a product. It is actively creating one. "In that sense, it begins to resemble a manufacturer and not just a mere incidental user."

The patient-specific nature of bioprinted organs does not provide the escape hatch one might expect. Dr. Adewale points to existing case law holding producers of customized, patient-specific items strictly liable. "The operative question is whether the defendant is in the business of producing or supplying the product, notwithstanding the scale of production at a given time. A product may be individually tailored, yet still produced within a structured, repeatable, and scalable system."

The Billing Problem

One detail that caught my attention: itemized billing. Where a hospital separates the cost of a bioprinted organ from its general medical services on an invoice, that starts to look like a product sale rather than clinical care. Dr. Adewale calls this "a doctrinal grey zone in which hospitals involved in bioprinting cannot be cleanly categorized as service providers, manufacturers, or commercial sellers."

This matters for procurement. If a hospital's billing practices inadvertently reclassify it as a commercial seller, every organ printed could trigger warranty and product recall obligations the institution never anticipated.

The BioCAD Designer Liability Gap

Perhaps most concerning for engineering teams is Dr. Adewale's assessment of bioCAD designer exposure. She calls it "the most underexplored legal exposure" in the entire supply chain.

"Product liability law still relies heavily on relatively traditional ideas of causation and physical manufacturing," she explains. This tends to anchor liability to whoever physically makes the final product. The bioCAD designer sits upstream, defining the organ's structure and biological outcome, but potentially too remote from the physical act of printing to attract direct liability.

That creates a mismatch between functional control and liability. "The exposure is not absent. It is just legally under-theorised." Engineering teams building bioCAD software and design tools should note this gap.

The Patent Problem

Intellectual property compounds the complexity. Existing patent frameworks struggle with modular technology, and bioprinting's layered architecture of design files, materials, and printing processes creates overlapping IP claims that existing frameworks cannot cleanly parse.

Dr. Adewale's framework attempts to provide what the law currently lacks: a structured way to assess outcomes while maintaining what she calls "a morally bounded space that prevents certain kinds of harm or unfairness from being justified purely on efficiency grounds."

The practical reality is messier. Engineers building bioprinting systems, hospitals deploying them, and investors funding the technology are operating in a legal vacuum that will eventually be filled by court decisions made without engineering input. That should concern anyone building products in this space.

M4S TAKE

My take: AI claims need scrutiny. The useful implementations reduce cycle time or defect rates in measurable ways. Vague promises about 'optimization' without specific metrics are usually marketing.

Simon McLoughlin